Connect Biopharma Holdings Limited
CNTB•NASDAQ•Healthcare•Biotechnology

About Connect Biopharma Holdings

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOBarry Quart
Founded2012
IPO DateMarch 19, 2021
Employees62
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Contact Information

Websitewww.connectbiopharm.com
Phone858 727 1040
Address
3580 CARMEL MOUNTAIN ROAD, SUITE 200 San Diego, California 92130 United States

Corporate Identifiers

CIK0001835268
CUSIPG23549101
ISINKYG235491019
SIC2834

Leadership Team & Key Executives

Dr. Barry D. Quart Pharm.D.
Chief Executive Officer and Director
David L. Szekeres J.D.
President
Lisa Peraza CPA
Senior Vice President of Finance
Jeff Cohn J.D.
General Counsel and Corporate Secretary
Sean T. Ristine
Vice President of Human Resources
Dr. Lei Sun Ph.D.
Vice President of Biologics and Head of CMC
Dr. Srikanth Pendyala M.D.
Senior Vice President of Clinical Development(Consultant)
Kimberly J. Manhard
Executive Vice President and Chief Development Officer